Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RIPECROP

Financiado

RNA-based cancer ImmunotheraPeutics to Enhance CROssPrimming

Cancer immunotherapy achieves unprecedented efficacy against a number of malignant diseases. Preclinical experiments in mouse models conclude that type-1 dendritic cells (cDC1) that present tumor antigens are an absolute requireme... ver más

30/09/2029

FUNOACION PARA LA...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

FUNOACION PARA LA INVESTIG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 12M€

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-22

ERC-2023-ADG: ERC ADVANCED GRANTS Scope:Objectives

I+D

Cerrada hace 1 año

0% 100% 100%

2 Participantes

FUNOACION PARA LA INVESTIG

2.41M€ | Lider

UPNA

88.50K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TrojanDC TrojanDC - A BREAKTHROUGH DEEP-TECH INNOVATION FOR CANCER IM... 75K€ Cerrado

NeoIDC Neoantigen Identification with Dendritic Cell Reprogramming 150K€ Cerrado

INCEPTOR Investigate the mode of action ofInvestigate the mode of act... 192K€ Cerrado

PID2020-112892RB-I00 INTEGRACION DE AGONISTAS DE 4-1BB (CD137), INTERLEUCINA-12,... 500K€ Cerrado

MiTE Developing the next generation of cis-targeting macrophage-T... 150K€ Cerrado

ImmuneSynapsEngagers Immune Synapse Engagement as a Novel Approach for Cancer Imm... 2M€ Cerrado

Duración del proyecto: 64 meses Fecha Inicio: 2024-05-22
Fecha Fin: 2029-09-30

Líder del proyecto

FUNOACION PARA LA INVESTIG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 12M€

Presupuesto del proyecto 3M€

Descripción del proyecto Cancer immunotherapy achieves unprecedented efficacy against a number of malignant diseases. Preclinical experiments in mouse models conclude that type-1 dendritic cells (cDC1) that present tumor antigens are an absolute requirement for most immunotherapy strategies to be efficacious, including those routinely applied to cancer patients at present. cDC1 cells are specialized in redirecting engulfed cell-associated antigens to the class I MHC antigen-presentation pathway in the context of IL-12 production and co-stimulation, at least when cDC1 cells are in the presence of moieties denoting viral infection. Such phenomena are key to prime anti-tumor T lymphocytes through a mechanism known as crosspriming. The RIPECROP project will test immunotherapy agents that enhance the numbers and performance of cDC1 in the tumor tissue microenvironment. The strategies will be based on mRNA constructs that will encode engineered forms of the cDC1 growth factor sFLT-3L, single-chain interleukin-12, cDC1 specific chemoattractants and bispecific costimulatory ligands targeted to surface proteins of cDC1 cells. The new therapeutic agents in the form of coding mRNAs will be expressed in vivo either intratumorally or using the mRNA-transferred liver as an internal biofactory to systemically produce the encoded proteins and their combinations. Innovative in-vivo screenings based on hydrodynamic gene transfer of the liver with various expression plasmids encoding heterodimerization systems will be performed to identify suitable new mRNA-based immunotherapeutic chimeric constructs to enhance antitumor T-cell crosspriming. Overall, a novel mRNA-based toolbox will be studied both in terms of anti-tumor efficacy and regarding the mechanisms of action, in such a manner, that crosspriming will become exploitable in combinatorial approaches for cancer immunotherapy.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores